TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16049191

Group type: EXPERIMENTAL
Intervention: Encoding memory task with low level of integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encoding memory task with high level of integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval memory task with low level of integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval memory task with high level of integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of event-related activation latencies
Number of subjects: 0
Study: 12616666

Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (0.8 mg/m2, maximum 1.5 mg, bid)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (1.5 mg) after a high-fat meal
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (1.5 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional tablets of everolimus (1.5 mg)
Number of subjects: 19
Study: 11094885

Group type: EXPERIMENTAL
Intervention: Rehabilitation complexes
Number of subjects: 85

Group type: COMPARATOR
Intervention: Various rehabilitation complexes
Number of subjects: 85
Study: 9026479

Group type: EXPERIMENTAL
Intervention: Bile acid perfusion (30% and 100% of bile acid output) with test meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Loxiglumide infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bile acids added to test meal (30% of bile acid output)
Number of subjects: 7
Study: 1393843

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propranolol 80 mg twice daily
Number of subjects: 94
Study: 3903501

Group type: EXPERIMENTAL
Intervention: Estrogen therapy combined with chemotherapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Estrogen combined with chemotherapy
Number of subjects: 112
Study: 30550503

Group type: EXPERIMENTAL
Intervention: Sutureless technique using Steristrip for skin apposition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcuticular technique with 6‐0 vicryl and 6‐0 prolene continuous subcuticular sutures
Number of subjects: 50
Study: 29557060

Group type: EXPERIMENTAL
Intervention: TMZ + RT
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: TMZ + IFNβ + RT
Number of subjects: 122
Study: 27630374

Group type: EXPERIMENTAL
Intervention: 440µg of intravitreal sirolimus administered on days 0, 30, 60, 90, 120, and 150
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 880µg of intravitreal sirolimus administered on days 0, 60, and 120
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 440µg of intravitreal sirolimus
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 880µg of intravitreal sirolimus
Number of subjects: 24
Study: 24191779

Group type: EXPERIMENTAL
Intervention: Nintendo Wii exergames with threat-framed health messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular physical education lessons with the same health messages
Number of subjects: 0
Study: 22682339

Group type: EXPERIMENTAL
Intervention: HPA genotyping using real time PCR and PCR-RFLP
Number of subjects: 600
Study: 18923386

Group type: EXPERIMENTAL
Intervention: Cholecalciferol every 2 weeks for 2 months (intensive phase) followed by every other month maintenance phase
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 94
Study: 17519730

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus of 0.7 microg/kg before infiltration with local anaesthetics (Group F1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus of 0.7 microg/kg plus 0.6 microg/kg fentanyl every 45 minutes (Group F2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam bolus of 0.05 mg/kg plus continuous infusion 0.08 mg/kg per hour (both groups)
Number of subjects: 100
Study: 15663280

Group type: EXPERIMENTAL
Intervention: Autologous chondrograft transplantation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abrasive techniques
Number of subjects: 50
Study: 11687773

Group type: EXPERIMENTAL
Intervention: Hyperthermia (434 MHz)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 40
Study: 9739441

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (CMF)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Temporary ovarian ablation by treatment with a LHRH analogue (Zoladex, Goserlin)
Number of subjects: 689
Study: 7981450

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 2663013

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 20
Study: 29535403

Group type: EXPERIMENTAL
Intervention: Amylose-rich wheat-based rusks (ARR)
Number of subjects: 10
Study: 27992239

Group type: EXPERIMENTAL
Intervention: Objective Criteria‐Based Rehabilitation (OCBR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care Rehabilitation (UCR)
Number of subjects: 40
Study: 26639149

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 269

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 269
Study: 24195627

Group type: EXPERIMENTAL
Intervention: High milk-calcium (CAL) meal (9 mg · kg(‐1) of body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (3 mg · kg(‐1) of body mass)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both trials (CAL and Control)
Number of subjects: 9
Study: 21822145

Group type: EXPERIMENTAL
Intervention: SL65.0472‐00 (20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sumatriptan (agonist)
Number of subjects: 24
Study: 17717114

Group type: EXPERIMENTAL
Intervention: Quercetin (1,000 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15128882

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12162481

Group type: EXPERIMENTAL
Intervention: Yellow lenses (29.7% light transmission)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Orange lenses (22.9% light transmission)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Red lenses (16.8% light transmission)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Grey lenses (10.3% light transmission)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No lens (control condition)
Number of subjects: 15
Study: 9651688

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (n = 43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Outpatient follow-up (n = 42)
Number of subjects: 85
Study: 8633188

Group type: EXPERIMENTAL
Intervention: 100 mg lithium carbonate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg lithium carbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2527199

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infused at a low rate of 0.005 micrograms/kg/min for 3 hours.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infused into the brachial artery at a rate of 0.005 micrograms/dl forearm tissue/min for 30 minutes.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 5
Study: 3259

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study: 31333730

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28362511

Group type: COMPARATOR
Intervention: 45 Gy in 30# twice daily radiotherapy (control arm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 66 Gy in 33# once daily radiotherapy (experimental arm)
Number of subjects: 100
Study: 25096893

Group type: EXPERIMENTAL
Intervention: Home-based rapid HIV-testing
Number of subjects: 2828
Study: 23041011

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 73
Study: 21952250

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study: 18423628

Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole (90‐mg bolus followed by 9‐mg/h infusion)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral lansoprazole (120‐mg bolus followed by 30 mg every 3 hours)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral lansoprazole
Number of subjects: 66
Study: 16886111

Group type: EXPERIMENTAL
Intervention: Repair with longitudinal incision and transverse suture on the vaginal posterior wall (study group, n=72)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Traditional repair with longitudinal incision and longitudinal suture (control group, n=74)
Number of subjects: 146
Study: 15545311

Group type: EXPERIMENTAL
Intervention: DB (10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DM (25 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MP (100 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Uncontrolled urine pH
Number of subjects: 36
Study: 11684534

Group type: EXPERIMENTAL
Intervention: Iron supplementation (105 mg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-iron diet (2.25 mg/d)
Number of subjects: 44
Study: 9835465

Group type: EXPERIMENTAL
Intervention: Tape Stripping (TS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no Tape Stripping)
Number of subjects: 68
Study: 7926098

Group type: EXPERIMENTAL
Intervention: Simple washing
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sephadex columns
Number of subjects: 98

Group type: COMPARATOR
Intervention: Percoll density gradient
Number of subjects: 98
Study: 2509120

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for the first six postoperative weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: No anti-inflammatory treatment (Control)
Number of subjects: 176
Study: 775991

Group type: EXPERIMENTAL
Intervention: Contraceptive medication
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study: 30562138

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28937062

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: No cryotherapy (Control)
Number of subjects: 62
Study: 26307614

Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Rheumatologist-led outpatient care (RLC)
Number of subjects: 349
Study: 23698496

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + bupivacaine 0.5%
Number of subjects: 126

Group type: COMPARATOR
Intervention: Saline 2 mL + bupivacaine 0.5%
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups (Dexamethasone and Control)
Number of subjects: 126
Study: 20673246

Group type: COMPARATOR
Intervention: Trigger point injection with 0.25% bupivacaine twice weekly, cyclobenzaprine chlorhydrate 10 mg/day, sodium dipyrone 500 mg every 8 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Classical and trigger point acupuncture twice weekly
Number of subjects: 30
Study: 19267264

Group type: EXPERIMENTAL
Intervention: 3MV intervention (n = 164)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Wait-list comparison condition (n = 174)
Number of subjects: 338
Study: 15919678

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 15580195

Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrapping
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional drying (control)
Number of subjects: 55
Study: 11726831

Group type: EXPERIMENTAL
Intervention: Daclizumab (2 mg/kg on POD 0 and 14), tacrolimus, mycophenolate mofetil, and corticosteroids on POD 0 and 1, then discontinuation of corticosteroids.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus, mycophenolate mofetil, and corticosteroids (standard regimen).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Daclizumab, tacrolimus, mycophenolate mofetil, and corticosteroids (discontinued after POD 1).
Number of subjects: 30
Study: 9128771

Group type: EXPERIMENTAL
Intervention: Combined scintigraphic evaluation and assessment of femoral shortening
Number of subjects: 88

Group type: COMPARATOR
Intervention: Scintigraphy alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low scintigraphic uptake with minor femoral shortening
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High scintigraphic uptake with minor femoral shortening
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High scintigraphic uptake with high degree of femoral shortening
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low scintigraphic uptake with high degree of femoral shortening
Number of subjects: 88
Study: 7968434

Group type: EXPERIMENTAL
Intervention: Active recovery (30 min at 40-50% VO2max)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Passive recovery (60-min seated rest)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 6

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 6
Study: 2444309

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) - 2 units daily for 3 days
Number of subjects: 202

Group type: COMPARATOR
Intervention: Colloid control - similar volume as FFP
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 202
Study: 30861099

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional Care
Number of subjects: 600
Study: 30176632

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract BNO 1055 added to standard treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard antihypertensive therapy (control group)
Number of subjects: 78
Study: 26907840

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training 3:1 (CT3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training 1:1 (CT1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Training (CON)
Number of subjects: 30
Study: 24123244

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relapse
Number of subjects: 0
Study: 22147112

Group type: EXPERIMENTAL
Intervention: BAY41-6551 400 mg every 12 hours (q12h)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BAY41-6551 400 mg every 24 hours (q24h) with aerosol placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo q12h
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BAY41-6551
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 18485453

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1158
Study: 17845589

Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg plus formoterol 6 microg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Fluticasone 125 microg plus salmeterol 25 microg
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Beclomethasone plus formoterol combination
Number of subjects: 228

Group type: COMPARATOR
Intervention: Fluticasone plus salmeterol
Number of subjects: 228
Study: 15759098

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 120
Study: 11928028

Group type: EXPERIMENTAL
Intervention: Microlaparoscopic cholecystectomy (3.5-mm LC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study: 9808229

Group type: EXPERIMENTAL
Intervention: 400 microg folic acid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 400 microg folic acid + 6 microg vitamin B-12
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 400 microg folic acid + 400 microg vitamin B-12
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 7649706

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (120 min/wk at 75% VO2max)
Number of subjects: 20
Study: 2655829

Group type: EXPERIMENTAL
Intervention: lyophilized allograft (LA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: exposure treatment (EP)
Number of subjects: 48
Study: 772759

Group type: EXPERIMENTAL
Intervention: Indomethacin (therapeutic doses)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (therapeutic doses)
Number of subjects: 67

Group type: COMPARATOR
Intervention: None (baseline comparison)
Number of subjects: 67

Group type: COMPARATOR
Intervention: None (pre-pubertal comparison)
Number of subjects: 67

Group type: COMPARATOR
Intervention: None (age group comparison)
Number of subjects: 67
Study: 31833621

Group type: EXPERIMENTAL
Intervention: Codonopsis lanceolata (CL) extract
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 80
Study: 31265139

Group type: EXPERIMENTAL
Intervention: Tailored education program provided in the hospital
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 390
Study: 28092106

Group type: EXPERIMENTAL
Intervention: Acupuncture at the EX-HN3 (Yintang) point
Number of subjects: 128

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 128
Study: 25651494

Group type: EXPERIMENTAL
Intervention: Unpreserved trehalose 30 mg/mL and sodium hyaluronate 1.5 mg/mL (TH‐SH, Thealoz Duo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unpreserved sodium hyaluronate, 0.15% (HA, Hyabak)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chloride, 0.9% (NaCl, Hydrabak)
Number of subjects: 60
Study: 24995488

Group type: EXPERIMENTAL
Intervention: Strength + stretch exercise program
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stretch alone exercise program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 57
Study: 21992924

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine with atazanavir/ritonavir (ATV/r)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine with efavirenz (EFV)
Number of subjects: 91
Study: 19391056

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser therapy every 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical preparations
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chemical peeling using trichloroacetic acid 25%
Number of subjects: 45
Study: 17720659

Group type: EXPERIMENTAL
Intervention: LPV/r 400/300 mg bid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LPV/r 667/167 mg bid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 36
Study: 15180728

Group type: EXPERIMENTAL
Intervention: Upper endoscope (E, diameter 9.8 mm)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard sigmoidoscope (S, diameter 13.3 mm)
Number of subjects: 160
Study: 15811145

Group type: EXPERIMENTAL
Intervention: Cerivastatin (800 microg nocte)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10575912

Group type: EXPERIMENTAL
Intervention: Omeprazole with amoxicillin and clarithromycin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Omeprazole with clarithromycin and metronidazole
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth with amoxicillin and metronidazole
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control endoscopy
Number of subjects: 224
Study: 8908921

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Light-cured resin sealant
Number of subjects: 50
Study: 1914413

Group type: EXPERIMENTAL
Intervention: Flurbiprofen SR
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diclofenac sodium SR
Number of subjects: 17
Study: 6614325

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg intravenously before operation)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Ticarcillin (5 g intravenously before operation)
Number of subjects: 209
Study: 30741832

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol 0.5 mg/kg and lidocaine 1.5 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (saline only)
Number of subjects: 84
Study: 30800079

Group type: EXPERIMENTAL
Intervention: Comprehensive 18-month intervention incorporating health behavior coaching and care coordination/care management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health behavior coaching and care coordination/care management delivered by a health coach and nurse.
Number of subjects: 0
Study: 27093939

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Number of subjects: 3350

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3350
Study: 24423410

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program‐derived print/telephone lifestyle intervention (13 telephonic sessions tailored to pregnant/postpartum women)
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Usual care practices (two pages of printed lifestyle recommendations sent to postpartum women via mail)
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program‐derived print/telephone lifestyle intervention
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 2320
Study: 23028897

Group type: EXPERIMENTAL
Intervention: 100 µg selenium/d
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 200 µg selenium/d
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 300 µg selenium/d
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 501